Fletcher, J. R., et al. (2021) Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. Nature ...

Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, ...

Researchers have identified two distinct mechanisms of drug resistance in C. difficile, but its ability to withstand antibiotics comes with downsides for the bacteria.

After colonization with C. difficile, the organism produces and releases the main virulence factors, the two large clostridial toxins A (TcdA) and B (TcdB). (Kachrimanidou, Microorganisms 2020, 8 ...

The contribution of Clostridium difficile toxin A and (TcdA and TcdB) to cellular intoxication has been studied extensively, but their impact on bacterial colonization remains unclear. By setting up 2 ...

When they used genetically engineered C. difficile strains that contained inactivated toxin genes and/or released a related C. difficile toxin called TcdA, mice infected with the TcdB-inactivated ...

C. difficile is considered one of the biggest antibiotic resistance threats in the USA - and caused an estimated 223,900 infections and 12,800 deaths in 2017, at a healthcare cost of more than $1 ...

About 500,000 C. difficile infections occur in the U.S. each year, and 15,000 people die from it, the Cleveland Clinic says.

Like the COVID vaccines, the C. difficile mRNA vaccine uses genetic material from the bacteria to train the immune system to recognize and respond in the event of future infections.

There were 86,000 hospital stays involving C. difficile in 1993, increasing to 349,000 in 2008 and then dropping to 337,000 in 2009.